NCT06504459 - Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 3, 2025

Primary Completion Date

October 11, 2027

Study Completion Date

May 1, 2028

Conditions

Acute Monocytic LeukemiaAcute Myeloid Leukemia

Interventions

DRUG

Azacitidine

Given IV or SC

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration and biopsy

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow aspiration and biopsy

DRUG

Cladribine

Given IV

DRUG

Cytarabine

Given SC

PROCEDURE

Echocardiography

Undergo ECHO

PROCEDURE

Lumbar Puncture

Undergo LP

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Venetoclax

Given PO

Trial Locations (1)

97239

RECRUITING

OHSU Knight Cancer Institute, Portland